Bionova Scientific, a full-service biologics contract development and manufacturing organization (CDMO) and subsidiary of global conglomerate Japan's Asahi Kasei, has announced the opening of a 10,000 square-foot state-of-the-art plasmid DNA (pDNA) development and production facility in The Woodlands, Texas, US.
Located less than 30 miles north of Houston, Texas, the new facility designs, develops and manufactures research-grade pDNA materials to support the cell and gene therapy field. With the global pharmaceutical market anticipated to reach almost $3 trillion by 2033, Bionova Scientific has positioned itself to effortlessly accommodate the market’s rapid growth.
Enabled by the new Texas facility, the company will expand its offerings beyond mammalian protein production and provide clinical to commercial-scale Current Good Manufacturing Practice (CGMP) production of pDNA by Q4 2025.
Plasmid DNA is a critical starting material for advanced therapeutics, including mRNA and viral vector-based cell and gene therapies (CGTs). Adding pDNA development and manufacturing services enhances Bionova Scientific’s established expertise in antibody and protein CDMO services, already offered via its recently expanded flagship facility in San Francisco’s Bay Area. Through these added services, Bionova is broadening its portfolio across biotherapeutic modalities to serve more customers.
As a core growth driver within Asahi Kasei’s Life Science group, Bionova continues to scale its presence to meet the evolving needs of the biopharmaceutical industry.
